Medication info
Losanin Plus Tablet

Losanin Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Pale yellow, oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 30 tablets/PTP (for export)
Approval status
Active

MFDS item code 200608255 · Notified 2006.08.31 · Insurance code 649800570

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when monotherapy has not produced the expected effect. 1. Substitution therapy: Treatment with the individually titrated combination of losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in patients with hepatic impairment requiring dose adjustment, because this drug cannot provide the initial dose of losartan potassium, 25 mg, for such patients.
Child dose
Children (under 18 years of age): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used to effectively control blood pressure in hypertensive patients whose blood pressure is not sufficiently controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when monotherapy has not produced the expected effect. 1. Substitution therapy: Treatment with the individually titrated combination of losartan potassium and hydrochlorothiazide may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia even though their blood pressure is controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. Continue to monitor the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose if creatinine clearance is 30 mL/min or greater. Use of this drug is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this drug is not recommended in patients with hepatic impairment requiring dose adjustment, because this drug cannot provide the initial dose of losartan potassium, 25 mg, for such patients.

Child dose

Children (under 18 years of age): As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be administered to certain patients, such as those who are allergic to this drug or its components, have severe renal impairment, liver disorders, are pregnant, or have specific electrolyte disturbances. Patients with hypotension or renal function issues should use this medication with extra caution, as blood pressure may drop too low or renal function may worsen, requiring regular monitoring. This medication may alter potassium levels in the blood, so expert consultation is necessary if taken with potassium supplements or other medications containing potassium. Due to the hydrochlorothiazide component, electrolyte imbalance may occur, and it is important to regularly monitor electrolyte status through blood tests. Dizziness or drowsiness may occur during treatment, so caution is needed when driving or operating machinery. Additionally, exposure to sunlight while taking this medication may increase the risk of skin cancer, so regular use of sunscreen and skin examinations are recommended. If any unusual symptoms or side effects occur during use, immediate consultation with healthcare professionals is necessary, especially if blood pressure drops too low or severe allergic reactions, skin rashes, or breathing difficulties arise, which require immediate action. This medication is not recommended for use in children or adolescents due to insufficient experience in this population. Finally, this medication should be stored in its original container and kept out of reach of children.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Lumbago
  • Dizziness
Show 143 more
  • Cough
  • Sinusitis
  • Upper respiratory tract infection
  • Rash
  • Angioedema
  • Skin peeling phenomenon
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina
  • Arrhythmia
  • Cerebrovascular accident
  • Myocardial infarction
  • Secondary atrioventricular block
  • Anorexia
  • Constipation
  • Toothache
  • Dry mouth
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Arthralgia
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramping
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle rigidity
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory impairment
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Hyperesthesia
  • Panic disorder
  • Sensory disturbance
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremor
  • Dyspnea
  • Epistaxis
  • Nasal congestion
  • Pharyngeal discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous sinus disorder
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Skin dryness
  • Petechial hemorrhage
  • Erythema
  • Flushing
  • Phototoxic reaction
  • Pruritus
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Visual impairment
  • Taste disturbance
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Polyuria
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Spasms
  • Gastric irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle spasms
  • Restlessness
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis
  • Yellow vision
  • Acute myopia
  • Acute angle-closure glaucoma
  • Choroidal exudate
  • Hypotension
  • Tachycardia
  • Hypokalemia
  • Hypochloremia
  • Hyponatremia
  • Polydipsia
  • Thirst
  • Somnolence
  • Drowsiness
  • Restlessness
  • Seizures
  • Myalgia
  • Muscle fatigue
  • Decreased urine output
  • Nausea
  • Weakness
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Intestinal vascular edema
  • Dry cough
  • Erythroderma
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a light-protective, tightly closed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius, avoiding extremely hot or cold environments.

Appearance and packaging

Appearance

Pale yellow, oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 30 tablets/PTP (for export)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.